Within the category of “Development of Treatments and Therapeutic Interventions,” the main pediatric TB research priorities were developing a treatment for active and latent TB in children, 10/13 (76.9); monitoring of electrolytes (potassium and magnesium) and albumin in the management of TB in children, 2/13 (15.4); and standardized language to describe barriers to TB treatment initiation, within the TB research and advocacy community, 1/13 (7.7). The gene discussed is ALB; the disease is tuberculosis.